Arkema

Sustained profitability despite lower sales prices

14/05/24 -"Sales in the Q1 declined as anticipated, but adjusted EBITDA demonstrated greater resilience. The figures were mixed compared to the consensus (sales: -2.0%; adjusted EBITDA: +2.6%; adjusted EPS: ..."

PDF page sample
Pages
67
Language
English
Published on
14/05/24
Download
You may also be interested by these reports :
29/07/26
BASF reported strong Q2 2026 gains driven by war-led pricing and volumes in core businesses. Surface Technologies benefited from metals trading, ...
29/07/26
Solvay’s Q2 results gained market appreciation; however, underlying uncertainties remain. Soda ash continues to face pricing pressure from Chinese ...
28/07/26
Air Liquide reported a solid performance for H126, meeting operating profit expectations. Revenue was softer due to energy price volatility (with no ...
23/07/26
Givaudan’s performance in the first half of the year was mixed. Revenue surpassed expectations, driven by strong results in the Fragrance & Beauty ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO